In this report, we focus on how companies can reach 2020 in a position to benefit from more favourable conditions thereafter.
The pharmaceutical industry is at a critical juncture. The tools to develop remarkable new medicines are materialising, demand for its products is increasing and the barriers to free trade are falling. But pharma also faces major economic and operational challenges, if it’s to capitalise on these opportunities and create more value for healthcare payers, providers and patients.
Many of the conditions that will determine what happens in 2020 are already in place. Most of the products that will be launched are already in the pipeline; the processes being used to develop them are similar to those used for the past 10 years; the prevailing management culture remains that of the late 20th century; and a demanding commercial environment looks set to continue.
So, what are the most important decisions senior management will need to make?
|Novemeber 2012||Pharma 2020- From vision to decision (Japanese)|
|Novemeber 2012||Pharma 2020- From vision to decision (French)|
|July 2011||Introducing the Pharma 2020 Series|
|February 2011||Pharma 2020: Supplying the future - Which path will you take?|
|December 2009||Pharma 2020: Taxing times ahead - Which path will you take?|
|April 2009||Pharma 2020: Challenging business models - Which path will you take?|
|February 2009||Pharma 2020: Marketing the future - Which path will you take?|
|June 2008||Pharma 2020: Virtual R&D - Which path will you take?|
|June 2007||Pharma 2020: The vision - Which path will you take?|